MedPath

Istaroxime

Generic Name
Istaroxime
Drug Type
Small Molecule
Chemical Formula
C21H32N2O3
CAS Number
203737-93-3
Unique Ingredient Identifier
W8I9H2TPPL
Indication

Investigated for use/treatment in heart disease.

Clinical Trials
Related News

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

Phase 1
Recruiting
Conditions
Cardiogenic Shock
Interventions
Drug: Placebo
First Posted Date
2023-08-03
Last Posted Date
2024-07-26
Lead Sponsor
Windtree Therapeutics
Target Recruit Count
20
Registration Number
NCT05975021
Locations
🇮🇱

Kaplan Medical Center, Reẖovot, Israel

🇺🇸

Oregon Health and Sciences University, Portland, Oregon, United States

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

Phase 2
Completed
Conditions
Cardiogenic Shock
Interventions
Drug: Placebo
First Posted Date
2020-03-27
Last Posted Date
2025-02-04
Lead Sponsor
Windtree Therapeutics
Target Recruit Count
90
Registration Number
NCT04325035
Locations
🇺🇸

Tufts Medical Center, Boston, Massachusetts, United States

🇦🇷

Hospital Italiano de Bueno Aires, Capital Federal, Buenos Aires, Argentina

🇦🇷

Santorio Guemes, Capital Federal, Buenos Aires, Argentina

and more 10 locations

Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a

Early Phase 1
Completed
Conditions
Heart Failure, Congestive
Interventions
Other: Exercise
First Posted Date
2016-05-13
Last Posted Date
2022-06-29
Lead Sponsor
Benjamin Levine
Target Recruit Count
26
Registration Number
NCT02772068
Locations
🇺🇸

The Institute for Exercise and Environmental Medicine, Dallas, Texas, United States

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

Phase 2
Completed
Conditions
Acute Decompensated Heart Failure
Interventions
Drug: Placebo
First Posted Date
2015-12-01
Last Posted Date
2023-05-24
Lead Sponsor
Windtree Therapeutics
Target Recruit Count
120
Registration Number
NCT02617446
Locations
🇮🇹

University of Milano-Bicocca, Milan, Italy

🇮🇹

University and Civil Hospital of Brescia, Brescia, Italy

🇨🇳

Lanzhou University No.2 Hospital, Lanzhou, Gansu, China

and more 8 locations

Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers

Phase 1
Conditions
Healthy
Interventions
Drug: 9% Saline (NS)
First Posted Date
2015-06-22
Last Posted Date
2015-06-22
Lead Sponsor
Lee's Pharmaceutical Limited
Target Recruit Count
32
Registration Number
NCT02477449
Locations
🇨🇳

The 307th hospital of chinese People's liberation army, Beijing, China

Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure

Phase 1
Withdrawn
Conditions
Heart Failure
Interventions
First Posted Date
2009-03-25
Last Posted Date
2014-10-23
Lead Sponsor
Debiopharm International SA
Registration Number
NCT00869115

Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients

Phase 2
Withdrawn
Conditions
Heart Failure
Interventions
Drug: Placebo
First Posted Date
2009-02-06
Last Posted Date
2014-10-23
Lead Sponsor
Debiopharm International SA
Registration Number
NCT00838253

A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function

Phase 2
Completed
Conditions
Heart Failure
Interventions
Drug: Placebo
First Posted Date
2008-02-15
Last Posted Date
2008-02-15
Lead Sponsor
sigma-tau i.f.r. S.p.A.
Target Recruit Count
120
Registration Number
NCT00616161
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy